Sino Biopharm
Sino Biopharmaceutical Limited (01177.HK) is a leading innovation-driven healthcare group in China, specialising in the entire pharmaceutical value chain from R&D to intelligent manufacturing and sales. Sino Biopharm is recognised globally for its growth and R&D capabilities, and has ranked among Pharm Exec’s Top 50 Global Pharmaceutical Enterprises for seven consecutive years, currently placing 39th worldwide and 2nd in China. Through its core subsidiaries, including Chia Tai Tianqing and Beijing Tide Pharmaceutical, the group remains committed to delivering innovative therapies to patients.
Sino Biopharm's drug pipeline in 2025 reflects a diverse and expanding portfolio across multiple therapeutic areas and drug types.
Sino Biopharm Group Co. Ltd. – 2025 Drug Pipeline Overview
Oncology- Strengths and Highlights
Pipeline spans a wide range of high-impact therapeutic areas:
- Oncology: Multiple assets targeting NSCLC, colorectal cancer, EGFR-mutant cancers, and broader immuno-oncology.
- Respiratory: COPD treatments with advanced trial progression.
- Metabolic & Liver Diseases: Global Phase III trials with regulatory recognition.
- Surgical/Analgesia: Long-acting pain relief options.
- Coagulation Disorders: Biologic therapies for hemostasis.
Advanced Modalities & Mechanisms
- Bispecific ADCs (e.g., TQB6411 targeting EGFR/c-Met): Cutting-edge antibody-drug conjugates.
- Checkpoint Inhibitors (e.g., TQB2450): Immuno-oncology agents aligned with global trends.
- Multi-target TKIs (e.g., Anlotinib): Broad-spectrum kinase inhibitors with multiple approved indications.
- Pan-PPAR Agonists (e.g., Lanifibranor): Innovative metabolic disease treatments with breakthrough designation.
Strong Clinical Momentum
- Bispecific ADCs (e.g., TQB6411 targeting EGFR/c-Met): Cutting-edge antibody-drug conjugates.
- Checkpoint Inhibitors (e.g., TQB2450): Immuno-oncology agents aligned with global trends.
- Multi-target TKIs (e.g., Anlotinib): Broad-spectrum kinase inhibitors with multiple approved indications.
- Pan-PPAR Agonists (e.g., Lanifibranor): Innovative metabolic disease treatments with breakthrough designation.
Commercial Readiness & Expansion
- Anlotinib (Focus V): Already approved for 9 cancer indications, with 3 more under review.
- Strategic Licensing: TQC3721 acquired from Lanova Medicines, showing proactive portfolio expansion.
Innovation Pipeline
- Novel Mechanisms: TD101 represents a new class of oral small molecules.
- Platform Potential: Early-stage ADCs and checkpoint inhibitors suggest scalable innovation.
